Published in Diabetes Care on June 01, 2009
A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab (2011) 1.19
Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs (2012) 0.91
Confusion Regarding Duration of Insulin Action: A Potential Source for Major Insulin Dose Errors by Bolus Calculators. J Diabetes Sci Technol (2014) 0.89
Evidence-based clinical use of insulin premixtures. Diabetol Metab Syndr (2013) 0.77
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia (2004) 1.75
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab (2006) 1.71
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab (2008) 1.41
Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med (2000) 1.39
Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol (2000) 1.03
Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care (1997) 1.01
Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol (2000) 0.98
A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care (2004) 0.95
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes (2004) 3.66
Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care (2008) 3.66
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care (2011) 1.78
Accuracy and reliability of continuous glucose monitoring systems: a head-to-head comparison. Diabetes Technol Ther (2013) 1.71
Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens (2006) 1.51
Blood glucose meter market: this world is undergoing drastic changes. J Diabetes Sci Technol (2013) 1.51
Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes. J Diabetes Sci Technol (2011) 1.50
Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device. J Diabetes Sci Technol (2008) 1.46
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant (2006) 1.42
A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. Diabetologia (2014) 1.38
Real-time improvement of continuous glucose monitoring accuracy: the smart sensor concept. Diabetes Care (2012) 1.37
Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center. J Diabetes Sci Technol (2012) 1.35
Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care (2013) 1.32
Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther (2014) 1.31
Continuous glucose monitoring with glucose sensors: calibration and assessment criteria. Diabetes Technol Ther (2003) 1.24
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther (2011) 1.21
Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care (2005) 1.19
Continuous glucose monitoring: reliable measurements for up to 4 days with the SCGM1 system. Diabetes Technol Ther (2003) 1.16
Cardiovascular control during exercise: insights from spinal cord-injured humans. Circulation (2003) 1.15
Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther (2011) 1.14
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care (2005) 1.10
Non-invasive glucose monitoring in patients with Type 1 diabetes: a Multisensor system combining sensors for dielectric and optical characterisation of skin. Biosens Bioelectron (2009) 1.08
Biosimilar insulin and insulin antibodies. J Diabetes Sci Technol (2013) 1.08
Hypoglycemia warning signal and glucose sensors: requirements and concepts. Diabetes Technol Ther (2003) 1.08
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes. Diabetes Care (2009) 1.01
Altered disease course after initiation of self-monitoring of blood glucose in noninsulin-treated type 2 diabetes (ROSSO 3). J Diabetes Sci Technol (2007) 1.00
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol (2015) 1.00
Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care (2007) 0.99
Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care (2010) 0.99
Glucose sensors and the alternate site testing-like phenomenon: relationship between rapid blood glucose changes and glucose sensor signals. Diabetes Technol Ther (2003) 0.98
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles. Diabetes Technol Ther (2009) 0.96
Novel findings on the metabolic effects of the low glycaemic carbohydrate isomaltulose (Palatinose). Br J Nutr (2010) 0.95
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol (2008) 0.93
Assessing the analytical performance of systems for self-monitoring of blood glucose: concepts of performance evaluation and definition of metrological key terms. J Diabetes Sci Technol (2013) 0.90
Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy. J Diabetes Sci Technol (2011) 0.89
Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear. Drug Deliv Transl Res (2015) 0.89
Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care: response to Staten et al. Diabetes Care (2010) 0.89
Nonlinear metabolic effect of insulin across the blood glucose range in patients with type 1 diabetes mellitus. J Diabetes Sci Technol (2010) 0.88
Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same? J Diabetes Sci Technol (2011) 0.88
Parameters affecting postprandial blood glucose: effects of blood glucose measurement errors. J Diabetes Sci Technol (2008) 0.88
Continuous glucose monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol (2013) 0.87
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One (2011) 0.84
Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Diabetes Metab Res Rev (2005) 0.83
Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time. Diabetes Technol Ther (2013) 0.83
System accuracy of blood glucose monitoring systems: impact of use by patients and ambient conditions. Diabetes Technol Ther (2013) 0.83
Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol (2009) 0.82
A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. Magn Reson Imaging (2003) 0.82
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One (2012) 0.82
Interrelations between diabetes therapy, self-monitoring of blood glucose, blood glucose and non-fatal or fatal endpoints in patients with type 2 diabetes / results of a longitudinal cohort study (ROSSO 5). Arzneimittelforschung (2007) 0.82
Continuous glucose monitoring during exercise in patients with type 1 diabetes on continuous subcutaneous insulin infusion. J Diabetes Sci Technol (2010) 0.81
Correlation between anthropometric parameters and abdominal fat volumes assessed by a magnetic resonance imaging method in patients with diabetes. Diabetes Technol Ther (2004) 0.81
Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diabetes Sci Technol (2007) 0.81
Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story? J Diabetes Sci Technol (2007) 0.80
Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol (2008) 0.80
(Analytical) accuracy of blood glucose meters and patients: how do they come together? J Diabetes Sci Technol (2013) 0.79
Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care (2002) 0.78
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technol Ther (2004) 0.78
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism (2004) 0.78
Natural history of alpha mannosidosis a longitudinal study. Orphanet J Rare Dis (2013) 0.78
The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial). PLoS One (2013) 0.77
AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care (2007) 0.77
The diabetes technologist: a practical solution in dealing with technology in everyday practice? J Diabetes Sci Technol (2012) 0.77
First-phase insulin secretion has limited impact on postprandial glycemia in subjects with type 2 diabetes: correlations between hyperglycemic glucose clamp and meal test. Diabetes Technol Ther (2010) 0.76
Future of diabetes-technology: certificate of competency for insulin pumps and continuous glucose monitors. J Diabetes Sci Technol (2012) 0.76
AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technol Ther (2009) 0.76
A 4-h hyperglycaemic excursion induces rapid and slow changes in major electrolytes in blood in healthy human subjects. Acta Diabetol (2011) 0.76
Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study. J Diabetes Sci Technol (2012) 0.76
Further development of artificial pancreas: blocked by patents? J Diabetes Sci Technol (2008) 0.76
Myocardial infarction and stroke in early years after diagnosis of type 2 diabetes: risk factors and relation to self-monitoring of blood glucose. Diabetes Technol Ther (2009) 0.76
Are type 2 diabetes patients who self-monitor blood glucose special? The role of confounders in the observational ROSSO study. J Diabetes Sci Technol (2009) 0.75
Biosimilar insulins: how will this story evolve? Diabetes Technol Ther (2012) 0.75
Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care (2007) 0.75
Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol (2015) 0.75
Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes. Diabetes Technol Ther (2009) 0.75
Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program. Curr Med Res Opin (2015) 0.75
Effect of C-peptide on glucose metabolism in patients with type 1 diabetes. Diabetes Care (2002) 0.75
[Practical aspects in the use of biosimilar insulins]. Dtsch Med Wochenschr (2016) 0.75
Journal of Diabetes Science and Technology: evolution of an electronic journal. J Diabetes Sci Technol (2012) 0.75